Mesenchymal stromal cells (MSC) from JAK2+
myeloproliferative neoplasms differ from
normal MSC and contribute to the
maintenance of neoplastic hematopoiesis by Ramos, Teresa L. et al.
RESEARCH ARTICLE
Mesenchymal stromal cells (MSC) from JAK2+
myeloproliferative neoplasms differ from
normal MSC and contribute to the
maintenance of neoplastic hematopoiesis
Teresa L. Ramos1,2, Luis Ignacio Sánchez-Abarca1,2,3, Beatriz Rosón-Burgo2,3,
Alba Redondo1,2, Ana Rico1,2, Silvia Preciado1,2, Rebeca Ortega1,2,
Concepción Rodrı́guez1,2,3, Sandra Muntión1,2, Ángel Hernández-Hernández4, Javier De
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Abstract
There is evidence of continuous bidirectional cross-talk between malignant cells and bone
marrow-derived mesenchymal stromal cells (BM-MSC), which favors the emergence and
progression of myeloproliferative neoplastic (MPN) diseases. In the current work we have
compared the function and gene expression profile of BM-MSC from healthy donors (HD-
MSC) and patients with MPN (JAK2V617F), showing no differences in the morphology, pro-
liferation and differentiation capacity between both groups. However, BM-MSC from MPN
expressed higher mean fluorescence intensity (MIF) of CD73, CD44 and CD90, whereas
CD105 was lower when compared to controls. Gene expression profile of BM-MSC showed
a total of 169 genes that were differentially expressed in BM-MSC from MPN patients com-
pared to HD-MSC. In addition, we studied the ability of BM-MSC to support the growth and
survival of hematopoietic stem/progenitor cells (HSPC), showing a significant increase in
the number of CFU-GM colonies when MPN-HSPC were co-cultured with MPN-MSC.
Furthermore, MPN-MSC showed alteration in the expression of genes associated to the
maintenance of hematopoiesis, with an overexpression of SPP1 and NF-kB, and a downre-
gulation of ANGPT1 and THPO. Our results suggest that BM-MSC from JAK2+ patients
differ from their normal counterparts and favor the maintenance of malignant clonal hemato-
poietic cells.







Citation: Ramos TL, Sánchez-Abarca LI, Rosón-
Burgo B, Redondo A, Rico A, Preciado S, et al.
(2017) Mesenchymal stromal cells (MSC) from
JAK2+ myeloproliferative neoplasms differ from
normal MSC and contribute to the maintenance of
neoplastic hematopoiesis. PLoS ONE 12(8):
e0182470. https://doi.org/10.1371/journal.
pone.0182470
Editor: Kevin D Bunting, Emory University, UNITED
STATES
Received: March 9, 2017
Accepted: July 19, 2017
Published: August 10, 2017
Copyright: © 2017 Ramos et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: The microarray
dataset is fully available from the GEO repository,
under the identifier: GSE87806.
Funding: Teresa Lopes Ramos is supported by a
fellowship by the Portuguese Fundação para a
Ciência e Tecnologia (SFRH/BD/86451/2012).
Sandra Muntion is supported by Red TerCel from
Instituto de Salud Carlos III (RD12/0019/0017).
Silvia Preciado is supported by a Universidad de
Introduction
Myeloproliferative neoplasms (MPN) are a group of clonal hematological disorders, arising
from hematopoietic stem/progenitor cells (HSPC) harboring genetic defects that promote
abnormal proliferation and expansion of mature myeloid cells. According to the 2008 classifi-
cation of the world health organization (WHO), the classical entities polycythemia vera (PV),
essential thrombocythemia (ET), and primary myelofibrosis (PMF)[2, 2] are included among
the Philadelphia-negative myeloproliferative disorders. The uniquely acquired somatic
JAK2V617F mutation is a clonal mutation that can be detected in the HSPC as well as in
mature hematopoietic cells[3, 4]. JAK2V617F mutation is estimated to be present in >95% of
PV and 50% of ET and PMF patients[1].
Emerging insight regarding the crosstalk between leukemic cells and their microenviron-
ment supports the notion that changes in the marrow stromal niche influences the prolifera-
tion, survival and selection of malignant cells[5]. Bone marrow (BM) is a three-dimensional
dynamic structure defined by a complex network of extracellular matrix (ECM) proteins and
non-hematopoietic cells, responsible for supporting the growth, maturation and maintenance
of HSPC[6]. Mesenchymal stromal cells (MSC) are multipotent progenitor cells, and impor-
tant components of the BM niche. They are a repository of cells that participates in bone devel-
opment, maintenance, and remodeling. MSC also are important in the regulation of HSPC
through the interaction with other stromal cells, diffusible environment factors, and the release
of ECM components[7, 8]. Conflicting results have been published about the role of BM-MSC
in the pathogenesis of MPN[9]. Apart from the absence of the somatic mutation JAK2V617F
in the BM-MSC of patients, little is known about the characterization and biological behavior
of these cells[10]. Some studies reported genetic and functional aberrations of BM-MSC in
MPN, which were followed by a decrease in proliferation rated and osteogenic capacities[11].
Others showed that MSC from PMF patients exhibited a persistent increase of their osteogenic
abilities[12].
In this study we analyzed the behavior of BM-MSC from MPN patients (PV and ET) with
the mutation in JAK2V617F. We excluded PMF patients due to the problems to obtain a repre-
sentative BM aspiration product. We initially characterized the biological function and gene
expression profile changes in BM-MSC from patients when compared to BM-MSC of healthy
donors (HD). Then, we established co-cultures between MSC cell lines (HTERT and HS5)
and the MPN cell line, to study if the leukemic cells were able to modify the genes related to
hematopoietic support.
Materials and Methods
Samples and ethical statements
Bone marrow (BM) aspirates from 37 healthy donors (HD) and 33 newly diagnosed MPN
patients. Median age of control samples (HD-BM) was 49 (range 31–73), 23 male and 14
female. Patient´s characteristics are summarized in Table 1.
Ethics
The study was conducted in accordance to ethical standards and principles expressed in the
Declaration of Helsinki. Informed consent was obtained from all donors and patients included
in the study, and approved by the local Ethics Committee of the Hospital Universitario de Sala-
manca (Committee´s name) with the reference number 2014/06/86.
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Cell lines
UKE-1 and SET cell line derived from patients diagnosed with MPN, homozygous for
JAK2V617F mutation, was used in the experiment. This MPN cell line was kindly donated by
Prof. António Almeida[13]. The stromal cell lines used were: hMSC-TERT[14], which was a
generous gift from Dr. Dario Campana and the cell line HS-5 purchased from ATCC (ATCC
CRL11882). The cell lines were cultured as previously reported[13, 15].
Isolation and culture of BM-MSC from MPN patients and HD
Bone marrow mononuclear cells (BM-MNC) were isolated and cultured in standard culture
medium as previously described[16]. In each passage MSC were cultured until approximately
Table 1. Clinical characterisitics of MPN patients.
Subject Gender Age (y) Hb (g/dL) Platelets 103/μL WBC 103/μL %JAK2V617F
PV1 F 46 16.9 775 11.1 17%
PV2 M 53 13.9 262 4.01 49%
PV3 F 52 17.3 649 8.11 33%
PV4 M 74 15.7 233 4.19 40%
PV5 F 72 16.4 454 14.13 90%
PV6 M 66 16.9 1041 17.6 46%
PV7 M 67 17.3 485 12.9 33%
PV8 F 69 16.7 356 5.87 33%
PV9 M 71 18.4 597 8.26 23%
PV10 F 70 16.8 387 17.3 75%
ET1 F 40 14.3 415 9.2 24%
ET2 F 51 14.1 596 9.17 16%
ET3 F 70 17.6 567 8.67 54%
ET4 M 52 13.5 567 8.96 11%
ET5 M 74 15.7 180 6.08 35%
ET6 F 37 14.7 484 6.56 21%
ET7 M 65 14.5 483 7.63 20%
ET8 M 69 14.9 293 6.79 32%
ET9 F 51 13.5 644 7.41 13%
ET10 M 72 11.8 472 7.98 48%
ET11 F 74 14.3 636 5.83 22%
ET12 M 73 12.3 1167 13.7 25%
ET13 F 45 15.5 648 10.5 12%
ET14 M 73 11.3 656 9.73 60%
ET15 F 56 16.1 856 8.5 20%
ET16 M 62 17 697 10.2 10%
ET17 M 31 16.6 168 3.78 30%
ET18 F 68 14.7 571 6.92 18%
ET19 M 74 15.8 387 11.6 16%
ET20 M 70 14.1 224 3.8 22%
ET21 F 67 15.8 1027 11.1 24%
ET22 F 50 15.3 517 7.78 15%
ET23 M 47 14 634 5.22 44%
F- Female, M- Male, PV–Polycythemia Vera, ET- Essential thrombocythemia, Hb–Hemoglobin, WBC- withe blood cells. %JAK2V617F –represents the
percentage of hematopoietic cells with the mutation in the bone marrow or in peripheral blood.
https://doi.org/10.1371/journal.pone.0182470.t001
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70–80% confluence was reached, cells were detached and re-seeded for culture expansion at a
density of 5000 cells/cm2. In the expansion cycle, cells counts were performed after Trypan
Blue (Gibco, InvitrogenTM) staining on a Neubauer chamber. Population doublings (PD)
were calculated for each group using the following equation: PD = log10(N)/log10(2), where N
is the number of cells harvested at the end of the culture per number of seeded cells[17, 18].
Isolated BM-MSC were characterized fulfilling the minimal criteria established by the Interna-
tional Society for Cellular Therapy (ISCT)[19].
For the immunophenotypic characterization of BM-MSC were performed according with
previously established protocols[15, 16, 20]. Adherent cells at passage 3 were harvested and
incubated using the following conjugated monoclonal antibody combinations: CD34-FITC,
CD73-PE, CD45-PerCPCy5.5, CD105-APC/ CD44-FITC, CD14-PE, CD19-PerCPCy5.5/
CD90-FITC, CD166-PE, HLA-DR-PerCPCy5.5 (all from Becton Dickinson–BioSciences,
except CD105 that was purchased from R&D systems). To control background fluorescence,
unstained MSC were also acquired and used as negative control. Expression of individual
markers was recorded, both as a percentage of positive cells and as mean fluorescence intensity
(MIF) after subtracting the baseline auto-fluorescence levels observed for MSC.
Data were analyzed using the Infinicyt program (Cytognos, Salamanca, Spain). In order to
compare the expression level of each antigen the mean channel fluorescence was calculated
subtracting the MSC without staining. For in vitro adipogenic and osteogenic differentiation
was performed as previously reported[20].
RT-PCR determination
Total RNA was extracted from BM-MSC and BM-MNC with Trizol (Invitrogen) and subse-
quent reverse transcription was carried out using the High Capacity kit (Applied Biosystems,
Foster City, CA, USA). Gene expression (S1 Table) was quantified by using commercial Taq-
Man Gene Expression Assays and the Step One Plus Real-Time PCR System (Applied Biosys-
tems). Relative quantification was calculated using the 2−ΔCt values where: ΔCt = CtGene—
CtGAPDH. Panel of genes used in RT-PCR assay in additional information.
Allelic discrimination assay for JAK2V617F in MSC
Twenty nanograms of genomic DNA from 9 samples of MSC from patients carrying the
JAK2V617F in their hematopoietic cells were amplified using a TaqMan SNP genotyping
assay (Thermo Fisher Scientific). This assay is based on the simultaneous use of two specific
fluorescent TaqMan probes (6FAM for V617F and VIC for wild-type) to differentiate the
amplification of each allele. DNA from a patient homozygous for the mutation (100%) was
used as positive control.
Gene expression profiling using microarrays: Determination and data
analyses
After assessment of RNA integrity (Agilent 2100 Bioanalyzer, Agilent), samples were hybrid-
ized in the platform Gene Chip Human Gene 1.0 ST array system (Affymetrix, Santa Clara,
CA), following manufacturer’s instructions. The microarray expression dataset is fully avail-
able from the GEO repository (https://www.ncbi.nlm.nih.gov/geo/) under the identifier:
GSE87806. Data analyses were performed in the R/Bioconductor statistical environment.
Microarrays were pre-processed and normalized with the RMA (Robust Multi-Array Average)
algorithm. The algorithm LIMMA was used for differential expression analysis. A second algo-
rithm SAM (Significance Analysis of Microarrays) was used to corroborate and validate the
results obtained with LIMMA. The genes selected as significant passed a cut threshold of
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FDR< 0.05 (Fold Discovery Rate). More details about the way these methods were applied are
provided in the Supporting Information. Top significant differentially expressed genes derived
from the LIMMA method, were submitted to functional enrichment analysis using the bioin-
formatics tool, DAVID Bioinformatics Resources 6.7 (http://david.abcc.ncifcrf.gov/)[21, 22].
The gene sets analyzed for functional enrichment were the most significant from List I (up-
regulated genes with FDR<0.03) and List II (up-regulated genes with FDR<0.02).
Apoptosis and cell cycle assays
For apoptosis assessment, the cells from the different experimental condition were stained
with Annexin V-PE using the PE annexin V apoptosis detection kit (BD) following the manu-
facturer´s instructions. For cell cycle, the cells were stained with propidium iodide (PI), using
the kit cycle tests (BD), according to manufacturer’s instructions. The samples were acquired
in a FACSCalibur flow cytometer and analyzed as previously described[23].
Immunobloting
Proteins cell extracts and western-blot was performed as reported previously[24] Primary anti-
bodies used were MYADM (kindly provided from Prof. Miguel A. Alonso[25]), NF-Kß, Ang-1
(both from Santa Cruz) GAPDH and Tubulin (Cell Signaling).
Immunofluorescence
For immunofluorescence experiments, BM-MSC were fixed with 4% paraformaldehyde and
was performed as previously described[26].
Isolation of hematopoietic progenitor cells
After density gradient separation, CD34+ cells were purified from BM-MNC or from leuka-
pheresis samples from 4 HD (with a male/female ratio of 3/1, median age 26.5 years; range 22–
46 years) by immunomagnetic cell separation (Miltenyi Biotec, Bergisch-Gladbach, Germany)
as previously described[20].
Hematopoietic support assessment
BM-MSC derived from JAK2V617F patients and HD were seeded at a density of 1X105cells/
well in 24-well plates and cultured overnight. Purified CD34+cells (1x105-2x105) from BM of
MPN patients and HD were co-cultured using a transwell membrane of 0.04μm (Costar, Corn-
ing NY, USA). After 48 hours of co-culture, HSPC were recovered and 5x103 cells were seeded
into methylcellulose MACS Media with Stem Cell Factor, GM-CSF, G-CSF, IL-3 and IL-6
(MethoCult H4534-Stem Cell Technologies, Vancouver, Canada) to quantify only the progeni-
tor cell colony-forming unit–granulocyte/macrophage (CFU-GM), according to the manufac-
turer’s instructions. After 14 days, CFU were enumerated and classified by morphology as
previously described[27].
Long-term bone marrow cultures (LTBMC)
BM-MSC from MPN patients and HD were maintained in culture until confluence was
achieved. The expansion medium was changed for LTBMC medium according to the methods
of Gartner and Kaplan with slight modifications and as previously described[20, 28]. During 5
weeks, cells were weekly harvested and plated in methylcellulose medium. After 14 days, col-
ony numbers were scored using an inverted microscope. Results were expressed as number of
CFU per 105 cells seeded and the total number of CFU present in the culture.
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Co-culture system
Human mesenchymal cell line hTERT and HS5 were plated at concentration of 105 cells/well
in a 6-well plate (Costar, Germany) overnight. Then the cells were incubated with the medium
from UKE-1 cells (that were previously centrifuged and filtered to eliminate the cells) or with
4x105 cells/mL of UKE-1, SET-2 and CD34+ cells (obtained from leukapheresis) in a transwell
system constituted by a polycarbonate membrane (3.0μm pore size, Corning Incorporated,
Costar). Cultures were maintained in a 5% CO2, humidified atmosphere at 37˚C for 72 hours.
After the time of culture MSC were recovered and processed for total RNA extraction.
Statistical analysis
Statistical analysis was performed using SPSS software version 21 (Chicago, IL, USA) and
GraphPad Prims version 5.00 for Windows (GraphPad Software). The values reported in the
figures are given as median with the interquartile range or with mean ± standard error of the
mean (SEM). Differences between populations were calculated using the Mann-Whitney tests
with Bonferroni corrections. A p-value <0.05 was considered to be statically significant. The
outliers were analyzed using the Grubbs´s test (Graph Pad).
Results
Characterization of BM-MSC derived from MPN-JAK2+ patients
Patient´s characteristics are summarized in Table 1, MPN diagnosis was established according
with 2016 revision to of the World Health Organization classification of myeloid neoplasms
and acute leukemia classification[29]. BM-MSC from patients with JAK2 mutation displayed
similar morphology compared to HD BM-MSC. Fig 1A shows no differences regarding prolif-
erative capacity (expressed in population doubling) between PV/ET-MSC and HD-MSC.
Immunophenotypic characterization, in accordance with the minimal definition criteria
established by the ISCT[19], presented in Fig 1B showed that both HD and MPN-MSC were
positive for the typical MSC markers, whereas they were negative for hematopoietic markers
or the MHC class II molecules, including HLA-DR. When analyzed the fluorescence intensity
of surface antigens, an increased expression of CD73, CD90 and CD44 was observed (Fig 1B)
in MPN-MSC compared to HD-MSC. In addition, a lower expression of CD105 was found
(p<0.01). Similar expression pattern were observed between PV-MSC and ET-MSC (S1 Fig).
Osteoblastic and adipocyte in vitro differentiation was achieved with similar efficiency
between both groups (Fig 1C). However, 1 out of 9 PV-MSC samples did not differentiate into
adipocytes and 2 out of 20 samples of ET-MSC did not differentiated, one into adipocytes and
another into osteoblasts. All HD-MSC samples were capable to differentiate into both lineages.
We verified in a set of 9 samples that the JAK2V617F mutation was absent in MSC derived
from patients carrying this mutation in their hematopoietic cells.
Cell cycle and apoptosis of MPN BM-MSC
No differences were observed between groups in the cell cycle, the percentage of G0/G1
(HD-MSC = 94.5% (86.9–98.4) n = 10; JAK2-MSC = 95.3% (66.4–97.9) n = 15) and S phase
(HD-MSC = 2.4% (0.4–12.93) n = 10; JAK2-MSC = 1.91% (0.24–33) n = 15) (Fig 2A). The per-
centage of apoptotic cells (annexin+/7AAD+) was lower (p = 0.0036) in JAK2-MSC compared
to controls (HD-MSC = 18.15% (3.8–67) n = 14; JAK2-MSC = 10% (0.1–23) n = 20) (Fig 2B).
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Fig 1. Characterization of BM-MSC from JAK2V617F patients and healthy donors. (A) The number of
population doublings (PD) in each passage was calculated using the following equation: PD = log10(N)/log10
(2), where N is the number of cells harvested at the end of the culture per the number of seeded cells, where
isolated from HD and JAK2+ PV and ET patients BM-MSC (Passage1 to Passage 3). (B) Mean fluorescence
intensity of positive surface marker expression of HD-MSC and MPN-MSC; HD-MSC n = 20 and JAK2-MSC
n = 30. Values indicate the mean ± SEM. (C) In vitro multilineage differentiation assays performed in HD-, PV-
and ET-MSC. Left-handed photos represent the negative controls (no induction medium applied). The photos
MSC from JAK2 patients favors neoplastic hematopoiesis
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MSC gene expression profile results
To obtain a global view of the differences between HD and MPN cells, the genetic profiles of
BM-MSC from 8 JAK2V617F patients (4 PV and 4 ET) and 10 HD were analyzed.
Compared to HD, a total of 169 genes were differentially expressed in BM-MSC from MPN
patients (S2–S4 Tables). Overall, 125 genes were up-regulated and 8 genes were down-regu-
lated in PV BM-MSC. In ET BM-MSC 8 genes were differentially up-regulated and 4 genes
down-regulated (Supporting information). Twenty-four differentially-expressed genes were
common in PV and ET-MSC (Fig 3A). Myeloid-associated differentiation marker (MYADM)
gene and myeloid leukemia factor 2 (MLF) gene were over-expressed in both PV and ET cases,
when independent comparisons to HD-MSC were performed. MYADM expression it was
found to be selectively expressed in human myeloid cells (from HD), and also significantly
increased in MPN cell lines[30]. In order to confirm the overexpression of this gene observed
in array, RT-PCR and WB were performed in the BM-MSC. We observed an over-expression
of MYADM (RNAm and protein) in PV and ET respect to healthy donors (Fig 3B).
Differential biological processes between BM-MSC from MPN patients
and healthy control
The differential signal pathways are shown according to the enrichment score value in Table 2.
The total genes and representative gene title in respective signal pathways are also shown. The
of the middle show osteogenic differentiation detected by alkaline phosphatase activity. Right-handed photos
show adipogenic differentiation detected fat staining with Oil-Red-O (20X).
https://doi.org/10.1371/journal.pone.0182470.g001
Fig 2. Apoptosis and cell cycle analysis of BM-MSC. (A) Graph bar chart that represents the percentage of apoptotic cells (AnnexinV/
7AAD positives), and representative FACS dotplot of annexinV/7AAD staining on BM-MSC.* p<0.05. (B) Percentage of cells in G1, S and
G2/M phase from HD-MSC, PV-MSC and ET-MSC. No differences were observed between groups.
https://doi.org/10.1371/journal.pone.0182470.g002
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differential signal pathways included endoplasmic reticulum, protein transport, GTPase activ-
ity and membrane/ transmembrane region.
BM-MSC from MPN patients promotes the expansion of leukemic cells
As represented in Fig 4A, the total number of CFU was similar when HD-HSPC were cultured
on healthy and neoplastic feeder layers. However, a significant increase (p<0.05) of CFU was
observed when CD34+ cells from JAK2 patients were cultured with MPN-MSC, showing their
capacity in promoting the expansion of functional leukemic progenitors cells. It was not
observed differences in the capacity to maintain JAK2-HSPC between BM-MSC from PV and
ET patients (S2 Fig).
LTBMC were performed to assess MPN-MSC capacity to support healthy hematopoiesis
for 5 weeks. Results showed that BM-MSC from JAK2 patients (n = 7) and from HD (n = 7)
exhibited a similar capacity to support normal hematopoiesis during the first 2 weeks. At the
Fig 3. Gene expression profile of BM-MSC from HD and MPN (ET and PV) patients. (A) Represents the number of genes Up and
Down regulated in each group when compared against HD group. (B) Gene and protein expression of MYADM gene tested in BM-MSC
from MPN patients and HD. Results were normalized with the housekeeping gene GAPDH. Results are represented by the median and the
interquartile range. HeLa cells were used as positive control.
https://doi.org/10.1371/journal.pone.0182470.g003
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3rd and 4th week, a significant increase of CFU production was observed (week 3—p = 0.021
and week 4—p = 0.0028) when HD-CD34+ cells were co-cultured with MPN-feeder layers (Fig
4B). At the fifth week no differences were observed when the HSPC were cultured with both
MSC (HD and MPN). For the LTBMC experiments we used 3 BM-MSC from PV patients and








Endoplasmatic reticulum 76 4.3 CYB5R3, SLC36A1, VAPB, MRVI1, ALG3, RCE1, ALG8, C14ORF1, CANT1, TAPBP,
ELOVL1, TMEM173, PLOD1, PIGB, RPL10, PSENEN, KDELR1, AGPAT1, KDELR3,
PGAP2, KDELR2, PIGU, PIGS, TECR, LPCAT4, UGT2B11, ASPHD1, ORMDL2,
LEPREL1, FKBP10, TRAPPC1, EXT2, SLC27A2, SEC61G, CLN6, EXTL3, DERL1,
CACNB1, UBE2V1, PPT2, CTSA, TRAM2, STT3A, SHISA5, EMD, PLP2, NPLOC4, ICMT,
PORCN, NCSTN, BFAR, C3ORF52, TXNDC11, LASS2, DPM2, TAPBP, BFAR, NRBP1,
SLC22A18, C16ORF70, COPZ1, TAGLN2, SLC35A4, NUP214, NECAP1, QSOX1,
AP2M1, HIP1, SCAMP2, NRM, KPNA6, VAMP2, FAF1, MGAT5, PEX11B, MPV17
Protein transport 75 3.15 SNAP29, RAB7A, DERL1, RAB5C, COPZ1, VPS52, RAB1C, RAB1B, NUP214, TRAM2,
NECAP1, KDELR1, SCAMP4, AP2M1, KDELR3, KDELR2, PRAF2, RAB8A, SCAMP2,
RABIF, RAB4B, STXBP1, TIMM22, TOM1L2, ARF3, ARF4, KPNA6, RAB15, SEC61G,
VPS25 GRPEL1, C16ORF70, CACNB1, CTSA, TRAM2, TOMM34, GDI1, ICMT, YWHAE,
YWHAH, YWHAQ, PAX6, FAF1, SLC16A13, SLC36A1, SLC22A18, SLC35A4, GOT2,
DIRC2, NDUFS4, ANO10, CYB5B, ATP6V1F, SLC35E1, TRAPPC1, RBP4, SLC39A11,
CACNB3, FXYD5, CYB561D2, TRAM2, SLC35B4, SLC4A8, SLC25A44, TCIRG1,
ATP5J2, NDUFA2, ATP5F1, SLC16A2, AFM, LASP1, SDHC, TAPBP, MAP1S, VAMP2.
GTPase activity 47 2.99 RAB7A, RAB5C, RAB4B, TUBB, GNB1, ARF3, ARF4, RAC1, RRAS, TUBA3D, RHOC,
TUBG1, TUBG2, GNG5, NKIRAS2, TUBB3, RHOG, RAB8A, KIF3C, RAB1C, RAB1B,
RAB15, GDI1, RABIF, ARHGAP1, CFL1, YWHAQ, ARHGDIA, ACTB, CRYAB,
HIST1H2BM, GORASP2, CALM3, PRPS1, CYB5R3, COPZ1, CACNB1, ILK, MSN,
AP2M1, TOMM34, MUC1, APOBEC3C, GOLGA7, PLSCR3, DYM, PRKACA
Membrane/Transmembrane
region
191 2.55 TGOLN2, SLC36A1, RNASEK, NRBP1, SLC22A18, PEAR1, VAPB, CSPG4, RAB1C,
VPS52, RAB1B, MPV17, RCE1, FAM119B, C14ORF1, COX5A, SLC35A4, TAPBP,
GOT2, OR8K1, ELOVL1, DIRC2, PLOD1, ILK, RRAS, PSENEN, TMEM185B, RNF34,
GNG5, SCAMP4, SCAMP2, C1ORF212, TECR, SIRPA, LPCAT4, MARK2, C1ORF85,
OR8J1, KIAA0090, TMEM106A, MGAM, RAB15, ASPHD1, NRSN2, TMEM184B, VAMP2,
MGAT5, NEU3, FAM171A2, EXT2, SEC61G, FAM171A1, MAVS, EXTL3, DERL1,
TMEM214, COPZ1, DAG1, CACNB1, UBE2V1, FXYD5, MANSC1, TRAM2, TMEM127,
GORASP2, RAC1, PTPLA, EMD, AP2M1, HIP1, MUC1, RAB8A, PRAF2, ATP5J2,
C17ORF101, COX8A, CD276, PPAPDC1A, ICMT, TMEM110, GPR137C, TMEM179B,
PORCN, BFAR, EI24, TXNDC11, LASS2, TBXA2R, ENG, PIP4K2C, DCXR, NYNRIN,
SLC16A13, CYB5R3, OR10A3, OR5H1, LRRC8A, GPR160, RAB5C, MRVI1, ALG3,
TMEM62, ALG8, FAM57A, CANT1, TMEM175, CD97, EFHD2, TMEM173, GOLGA7,
NDUFS4, SMAGP, PIGB, NECAP1, RHOC, MSN, TM9SF4, KDELR1, RHOG, COX16,
TUBB3, TMEM104, ANO10, AGPAT1, TOMM34, KDELR3, KDELR2, PGAP2, FLOT2,
RAB4B, PIGU, STXBP1, PIGS, CYB5B, SLC9A3R1, MYADM, TIMM22, PRKD1,
KIAA1161, CLECL1, NRM, SLC35E1, ZDHHC12, UGT2B11, MOSPD3, ORMDL2,
MFSD11, C2ORF24, SLC27A2, CLN6, SNAP29, USP30, SLC39A11, SAMM50, CD248,
PCDHGC5, ZDHHC18, ITM2C, CYB561D2, STT3A, SHISA4, SLC35B4, SHISA5,
PLEKHO1, SLC4A8, HRCT1, SLC25A44, MANBAL, SELPLG, QSOX1, TEX261, GBA,
TCIRG1, PTPRB, PLP2, NDUFA2, ATP5F1, TMEM53, AXL, NLGN2, CBARA1, NID2,








RNA binding/ RNA recognition
motif, RNP-1
9 1.46 DDX55, SFRS5, SURF6, ZMAT3, RPS14, SART3, EWSR1, RPS3, SAFB2
structural molecule activity 8 1.32 ISCU, RPL23, COL21A1, RPS14, RPL7L1, COL24A1, COL16A1, RPS3
zinc finger region 8 1.08 ZNF516, ZNF236, ZNF274, KLF9, YY1, PRDM5, ZNF460, ZNF498
extracellular matrix/ biological
adhesion
10 1.06 SMOC2, COL24A1, COL16A1, NTN1, COL21A1, IL16, ADAM17, PARD3, TNFRSF10B,
GABRB3
https://doi.org/10.1371/journal.pone.0182470.t002
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4 samples from ET patients, we observed that ET-MSC showed more capacity to maintain the
HD-CD34+ cells, without differences between the groups.
BM-MSC from JAK2V617F patients express different expression pattern
of hematopoietic supportive genes
Given the changes observed in the capacity of MPN-MSC to support the formation and expan-
sion of healthy and leukemic HPC, quantitative RT-PCR was performed to assess the expres-
sion of genes involved in hematopoiesis maintenance. The genes studied were CXCL12,
Fig 4. Capacity of MPN-MSC to support hematopoietic progenitor cells. (A) Selective protection of leukemic hematopoiesis by
MPN-MSC. Left-handed graphic shows the total colony-forming unit (CFU-GM) from HD-CD34+ cells after 48h of culture with HD-MSC
(n = 7) and MPN-MSC (n = 7), no differences were observed between groups. Middle-handed shows CFU-GM from JAK2V617F-CD34+
cells after culture with HD-MSC (n = 4) and MPN-MSC (n = 6), showing a significant increase when leukemic progenitor cells were cultured
with MPN stroma. Right-handed graphic showed the results are expressed as the ratio between CFU-GM obtained with CD34+ cells that
had been co-cultured with HD-MSC or MPN-MSC and CD34+ cells without MSC. The results are showed as absolute CFU-GM per 5000
CD34+ cells seeded in methylcellulose, after 14 days in culture. (B) Capacity of MPN-MSC to maintain HD-HPC in LTBMC. Total of CFU-GM
from HD-CD34+ cells after 5 weeks in co-culture with HD-MSC (n = 7) and MPN-MSC (n = 7). Total BFU-e. Total number of colonies (CFU),
results shown are expressed as the mean of CFU±SEM. * p<0.05 ** p<0.01.
https://doi.org/10.1371/journal.pone.0182470.g004
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Angiopoetin-1 (ANGPT1), nuclear factor kappa B (NF-kB), Jagged-1 (JAG-1), bone morpho-
genetic protein 2 (BMP-2) secreted phosphoprotein 1 (SPP1), thrombopoietin (THPO), c-KIT
and tumor necrosis factor (TNF) (Fig 5). A downregulation of ANGPT1 (Fig 5A) was observed
in ET and PV-MSC. However, an infra-expression of BMP2 and THPO with significant differ-
ence was observed in ET-MSC, when compared to HD-MSC. An overexpression of NF-kB
was observed in both MPN-MSC (PV and ET) when compared to HD-MSC (Fig 5B). Regard-
ing the expression of SPP1, it was observed an overexpression just in ET-MSC (Fig 5C).
Western blot studies of ANGPT1, NF-kB and immunofluorescence assays for CXCL12 were
performed. As shown in Fig 6A, MPN-MSC had a higher protein expression of NF-kB whereas
almost no expression of ANGPT1 was detected. For CXCL12 expression study (Fig 6B),
immunofluorescence showed a decrease in CXCL12 expression in MPN-MSC compared to
HD-MSC.
Cell line co-culture studies
Several lines of evidence suggest that the establishment and progression of MPN can be driven
from the crosstalk between the mutated HSPC and the BM microenvironment[5, 31]. In this
set of experiments we analyzed if an MPN cell line (UKE-1 and SET-2) with the mutation in
JAK2 can change the expression of important key genes, important in the hematopoiesis main-
tenance, in two different healthy mesenchymal cell lines (hTERT and HS5).
hTERT and HS5 cell lines were maintained in culture with UKE-1, SET2 or CD34+ cells
(healthy hematopoietic compartment) (transwell) for 72h. Then, RNA from mesenchymal cell
lines was isolated and the expression of angiopoetin-1, NF-kB and CXCL12 was studied.
The leukemia-cell- changes in BM-MSC were different that those induced by CD34+ cells.
Was observed that the culture of leukemic cells (UKE-1 and SET-2) induce changes the expres-
sion of CXCL12 in the MSC (healthy). In the case of ANGPT1 expression and a significant
increase was observed when both MSC (HS5 and hTERT) were cultured with healthy or neo-
plastic hematopoietic cells. However, the MSC co-cultured with leukemic cells presented
higher expression of this gene (Fig 7). Regarding NF-kB, was observed a decrease in the
expression of this gene, when hTERT cells were co-cultured with SET-2 cells.
Fig 5. Differential expression of genes related to hematopoiesis in MPN-MSC. RT-PCR was used to determine the expression level of
the different genes associated with maintenance of hematopoiesis. GAPDH was used as housekeeping to normalize the results. In the
scatter plot graphic are represented by the median and the range.
https://doi.org/10.1371/journal.pone.0182470.g005
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Discussion
An increasing number of reports support the fact that mutated HSPC can modify the BM
stroma, and these modifications create a positive feedback loop that plays an essential role in
MPN progression[5, 31]. Since BM-MSC constitutes a relevant component of the tumor
microenvironment in hematological malignancies, in this study we characterize BM-MSC
from JAK2V617F patients. The evidence of the concept in which an altered stroma endorsed
the clonal HSPC in the development and progression in MPN has been gaining strength[12,
32]. Few and contradictory results of some reports have been described regarding the charac-
terization of BM-derived MSC from negative Ph- MPN patients. Regarding the proliferative
and differentiation capabilities of MPN-MSC, we did not observe any glaring differences with
HD-MSC. Our results are in accordance with other reports, where the MSC from neoplastic
patients do not evidence differences with HD-MSC[12, 33]. However, some studies reported
that MSC from MPN patients, mainly from PMF patients, showed slower proliferation rate
and reached senescence at earlier passages[11]. Regarding the immunophenotypic characteri-
zation of MPN-MSC, MFI expression from some molecules was different, showing an
Fig 6. Protein expression of NF-ƙB, ANGPT-1 and CXCL12 in MPN-MSC. (A) Western Blot of NF-ƙB and ANGPT-1 in
MPN and HD-MSC. (B) Representative image of CXCL12 expression in the MSC by immunofluorescence. HD-MSC shows
more CXCL12 (red) than the positive control (HeLa cells) and the MPN-MSC. In green shows tubulin. Scale: 0–50μm.
https://doi.org/10.1371/journal.pone.0182470.g006
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Fig 7. Expression of NF-ƙB and ANGPT-1 and CXCL12 by real-time PCR in MSC cell lines (hTERT and
HS5) after co-culture with UKE-1 cells. Results were normalized with the housekeeping gene GAPDH.
Results are represented by the median and the interquartile range. (A) Angiopoetin 1. (B) NF-ƙB. (C)
CXCL12. The control HS5 and hTERT represents the cells that were co-cultured for 72h with UKE cells
(transwell) n = 10.
https://doi.org/10.1371/journal.pone.0182470.g007
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increased MIF for CD73, CD90 and CD44, and decreased of CD105. Numerous studies have
previously described discrepancies in the MFI of these markers in the MSC from other hema-
tological disorders[34–37]. Endoglin CD105 is an important molecule in osteoblasts and adi-
pocyte differentiation process[38]. CD44 (hyaluronan receptor) is involved in cell adhesion,
migration, and homing of MSC[39]. CD44 activation leads to the stimulation of multiple
downstream pathways including TGF-ß signaling in the MSC[40]. The GPI-anchorage pro-
teins, CD73 (ecto-5’ nucleotidase) and CD90 (Thy-1), are signal transduction molecules in the
human immune system and mediators of cell-cell and cell-matrix interactions. It has been
demonstrated that CD90 knockdown in the MSC facilitates osteogenic and adipogenic differ-
entiation[41]. Exogenous expression of CD90-non-expressing fibroblasts results in RhoGT-
Pase activation[42]. We also study the presence of the mutation JAK2V617F in the MSC from
patients, which was negative in our study, as it has been previously reported[10].
Regarding gene expression profiling, our results showed a differential expression pattern in
PV and ET-MSC when compared to HD-MSC. Specially, PV-MSC showed the highest num-
ber of overexpressed genes. Biological analysis showed that these genes are related to endoplas-
mic reticulum processing, protein transport and GTPase activity. These signaling pathways are
important in cell differentiation, organization and dynamics of actin cytoskeleton, and cell
migration[43, 44]. From all overexpressed genes we selected MYADM as an example to con-
firm our genomic studies, which is a gene involved in the hematopoietic process and is up-reg-
ulated during myeloid differentiation[30]. MYADM is a MAL family protein, with eight
transmembrane regions located at the plasma membrane. In endothelial cells, MYADM has
the capacity to change their migration capacity and control the endothelial inflammatory
response[45]. Further studies will be necessary to explain the impact of MYADM overexpres-
sion in the MSC from MPN patients. A number of other genes are differentially expressed
between normal MSC and MSC from JAK2V617F patients. Their implications and functional
validation warrants future experiments. As an example, our group has recently shown the role
of the expression of HDAC8 in MSC from these patients [46].
One of the most important functional properties of BM-MSC is their capacity to support
hematopoiesis. One of our main objectives in this study was to functionally assess the differ-
ences in this hematopoietic-supporting ability between BM-MSC from MPN-patients and nor-
mal BM-MSC. Two sets of experiments were performed. Firstly, we analyzed the capacity of
BM-MSC to promote clonogenic growth of HSPC. Interestingly, we observed an increase in
colony formation when the CD34+ cells from JAK2V617F patients were maintained with
BM-MSC from MPN patients, providing a competitive advantage for leukemic cells. Results
from other groups have suggested that malignant stroma promotes the survival and prolifera-
tion of mutated hematopoietic progenitor cells [5, 31]. Secondly, we assessed MPN-MSC
capacity to maintain HD-HPC in a long-term culture system. Although we did not observe dif-
ferences in the total number of CFU-GM produced, the weekly evaluation of the number of
colonies generated, showed a significant increase in the number of CFU-GM for the HD-HPC
that were co-cultured with JAK2-MSC. Previous studies in this setting have shown contradic-
tory results. There are some reports describing a severely compromised ability to maintain
HD-HSPC in MPN-expanded osteoblasts and in human MSC from patients with classical
Philadelphia-negative MPN[11, 31]. Conversely, others have indicated that MPN-MSC exhibit
similar long-term hematopoiesis support ability compared to HD-MSC[12].
In order to analyze which mechanism could be involved in this increased functional capac-
ity, we analyzed the expression of some genes known to be directly or indirectly involved in
hematopoietic support. In MPN, decreased expression of CXCL12 by osteoblasts or by Nestin+
cells has been associated with the enhancement of the mobilization and loss of normal HSPC
[47, 48]. Immunofluorescence studies showed a decrease in the expression of CXCL12 in the
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MPN-MSC, showing that our results are in agreement with data from other authors. Other
genes related to hematopoietic support were also analyzed. A decrease in the expression of
ANGPT1 and an increase of NF-KB, THPO and SPP1 expression in MPN-MSC were
observed. ANGPT1 is a gene that regulates angiogenesis, which in the hematopoiesis setting
has been associated to the induction of quiescence in HSPC through the interaction with the
Tie-2 (CD90) receptor, increasing the adhesion of HSPC to osteoblasts in the BM[49]. Recent
studies reported that BM-MSC from leukemia patients express NF-ƙB at higher levels than
normal BM-MSC[50]. They also showed that the activation of NF-ƙB signaling can be induced
by the leukemic cell, playing a pivotal role in the development of leukemia chemoresistance.
Other important HSPC-maintenance transcription factor, THPO, was infra-expressed in
ET-MSC. THPO is a very important cytokine in the regulation of megakaryocyte development
and platelet production, and it is also involved in the regulation of HSPC survival and prolifer-
ation[51]. THPO/ MPL signaling is involved in the HSPC niche regulation, maintaining
LT-HSPC quiescence in the osteoblastic niche[52]. In the study reported by Schepers, they
identified the role of THPO and CCL3 by which leukemic myeloid cells stimulate MSC to
overproduce osteoblasts during BM remodeling in the MPN development[31]. We also
observed an increase of SPP1 in the MPN-MSC when compared to HD-MSC, some studies
showing alteration in the transcriptome and functional analyses with an increased osteogenic
potential and a TGFβ1 signaling signature in the MSC from PMF[12].
Recently, it has been discussed how leukemic hematopoiesis could affect the BM-stroma to
create a self-reinforcing leukemic niche that promotes leukemia progression, while negatively
affecting normal HSPC function. Our findings, in the present work, show a deregulated
expression profile affecting some genes involved in HSPC maintenance. In contrast to what
has been reported, a profound deregulation of these genes was found in the MSC from patients
with PMF, where the fibrotic state is well established[11, 12, 53]. In our study, the majority of
MSC were isolated from BM of MPN at diagnosis, suggesting that during MPN evolution
there are genetic alterations involving BM-MSC, which likely may influence disease behavior.
It will be interesting to follow up the expression of these genes, and to study if they change dur-
ing disease progression. Thereafter we established co-culture of hTERT and HS5 with UKE
cells, SET cells (MPN cell line) and with CD34+ cells (HD), to study the alterations in the
expression of important genes (CXCL12, NF-ƘB and Angiopoetin1) induced by leukemic
cells. We observed that after 72 hours of culture with MPN cell lines, a significant decrease of
CXCL12 expression and an increase of ANGPT1 expression were observed in both MSC cell
lines. These results demonstrate the capacity of leukemic cells to interact with stromal cells.
In summary, we have shown that BM-MSC from JAK2V617F patients display different
immunophenotype expression, gene expression profile and alterations in the expression of
genes related to hematopoietic support. We also observed that MPN-MSC may protect the
neoplastic cells by increasing their colony formation capacity. Our results provide new insights
to understand the biological role of BM-MSC in the pathophysiology of JAK2V617F MPN.
Supporting information
S1 Fig. Multiparametric flow cytometry immunophenotyping. Left panel (A) shows repre-
sentative dot-plots of stained BM-MSC from HD and JAK2V617F patients (ET and PV). In
the right panel (B) it can be observed scatter dot plot of positive surface marker expression in
the BM-MSC from the different groups. (D) Representative histograms of BM-MSC from HD
and MPN patients. The line represents the median with interquartile range. MIF–Mean Fluo-
rescence Intensity. ( p<0.05).
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S2 Fig. Hematopoietic supporting capacity of MPN-MSC. (A) Graphic shows the total col-
ony-forming unit (CFU) from JAK2V617F-CD34+ cells after 48h of culture with PV-MSC and
ET-MSC, no differences were observed between groups (B) Capacity of MPN-MSC to main-
tain HD-HPC in LTBMC. Total of CFU-GM from HD-CD34+ cells after 5 weeks in co-culture
with PV-MSC (n = 3) and ET-MSC (n = 4).
(TIF)
S1 Table. Panel of genes used in RT-PCR assays.
(DOCX)
S2 Table. Differential Up (red) Down (green)–regulated expression genes in BM-MSC
from PV patients (PV-MSC) contrasted against healthy controls (HD-MSC).
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S3 Table. Differential Up (red) Down (green)–regulated expression genes in BM-MSC
from ET patients (ET-MSC) contrasted against healthy controls (HD-MSC).
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